CN1205914C - 化妆品组合物 - Google Patents
化妆品组合物 Download PDFInfo
- Publication number
- CN1205914C CN1205914C CNB998130915A CN99813091A CN1205914C CN 1205914 C CN1205914 C CN 1205914C CN B998130915 A CNB998130915 A CN B998130915A CN 99813091 A CN99813091 A CN 99813091A CN 1205914 C CN1205914 C CN 1205914C
- Authority
- CN
- China
- Prior art keywords
- acid
- compositions
- weight
- skin
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 239000002537 cosmetic Substances 0.000 title claims description 17
- CNVZJPUDSLNTQU-SEYXRHQNSA-N petroselinic acid Chemical compound CCCCCCCCCCC\C=C/CCCCC(O)=O CNVZJPUDSLNTQU-SEYXRHQNSA-N 0.000 claims abstract description 32
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 33
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 18
- 229960004275 glycolic acid Drugs 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 239000004310 lactic acid Substances 0.000 claims description 9
- 235000014655 lactic acid Nutrition 0.000 claims description 9
- JKRDADVRIYVCCY-UHFFFAOYSA-N 2-hydroxyoctanoic acid Chemical compound CCCCCCC(O)C(O)=O JKRDADVRIYVCCY-UHFFFAOYSA-N 0.000 claims description 3
- 230000003796 beauty Effects 0.000 claims description 3
- YDZIJQXINJLRLL-UHFFFAOYSA-N 2-hydroxydodecanoic acid Chemical compound CCCCCCCCCCC(O)C(O)=O YDZIJQXINJLRLL-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 239000002085 irritant Substances 0.000 abstract description 3
- OXEDXHIBHVMDST-UHFFFAOYSA-N 12Z-octadecenoic acid Natural products CCCCCC=CCCCCCCCCCCC(O)=O OXEDXHIBHVMDST-UHFFFAOYSA-N 0.000 abstract 1
- CNVZJPUDSLNTQU-UHFFFAOYSA-N Petroselaidic acid Natural products CCCCCCCCCCCC=CCCCCC(O)=O CNVZJPUDSLNTQU-UHFFFAOYSA-N 0.000 abstract 1
- 229940061720 alpha hydroxy acid Drugs 0.000 abstract 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 abstract 1
- AQWHMKSIVLSRNY-UHFFFAOYSA-N trans-Octadec-5-ensaeure Natural products CCCCCCCCCCCCC=CCCCC(O)=O AQWHMKSIVLSRNY-UHFFFAOYSA-N 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 28
- 210000003491 skin Anatomy 0.000 description 21
- 102000004125 Interleukin-1alpha Human genes 0.000 description 19
- 108010082786 Interleukin-1alpha Proteins 0.000 description 19
- -1 polydimethylsiloxane Polymers 0.000 description 19
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 13
- 229960002986 dinoprostone Drugs 0.000 description 13
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 12
- 239000011248 coating agent Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 150000001261 hydroxy acids Chemical class 0.000 description 8
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 206010040880 Skin irritation Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 6
- 229960003471 retinol Drugs 0.000 description 6
- 235000020944 retinol Nutrition 0.000 description 6
- 239000011607 retinol Substances 0.000 description 6
- 230000036556 skin irritation Effects 0.000 description 6
- 231100000475 skin irritation Toxicity 0.000 description 6
- 235000021355 Stearic acid Nutrition 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 4
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000007764 o/w emulsion Substances 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 229940100460 peg-100 stearate Drugs 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000001072 coriandrum sativum l. fruit oil Substances 0.000 description 3
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 229960001679 octinoxate Drugs 0.000 description 3
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- 239000000516 sunscreening agent Substances 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 2
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 2
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000010473 blackcurrant seed oil Substances 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 229940086555 cyclomethicone Drugs 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940108325 retinyl palmitate Drugs 0.000 description 2
- 235000019172 retinyl palmitate Nutrition 0.000 description 2
- 239000011769 retinyl palmitate Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229950011392 sorbitan stearate Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- MZIIZQULXKCMRT-UHFFFAOYSA-N (3-hydroxy-2-methoxyphenyl)-phenylmethanone Chemical compound COC1=C(O)C=CC=C1C(=O)C1=CC=CC=C1 MZIIZQULXKCMRT-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SAMYFBLRCRWESN-UHFFFAOYSA-N 16-methylheptadecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC(C)C SAMYFBLRCRWESN-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 1
- QWVUXEBWAZOACQ-UHFFFAOYSA-N 2-(hydroxymethyl)-2-[[2-hydroxy-3-(16-methylheptadecoxy)propoxy]methyl]propane-1,3-diol Chemical compound CC(C)CCCCCCCCCCCCCCCOCC(O)COCC(CO)(CO)CO QWVUXEBWAZOACQ-UHFFFAOYSA-N 0.000 description 1
- BBFCZCZRPXGONA-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol Chemical compound OCCN(CCO)CCO.OCCN(CCO)CCO BBFCZCZRPXGONA-UHFFFAOYSA-N 0.000 description 1
- NIIRRKXWTSGTNQ-UHFFFAOYSA-N 2-hydroxyoctanoic acid Chemical compound CCCCCCC(O)C(O)=O.CCCCCCC(O)C(O)=O NIIRRKXWTSGTNQ-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- VMZXVUUFTRMSRG-UHFFFAOYSA-N 9-ethylcarbazol-2-amine Chemical compound C1=C(N)C=C2N(CC)C3=CC=CC=C3C2=C1 VMZXVUUFTRMSRG-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000586291 Ammopiptanthus mongolicus Species 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- AINDYVWBKIVNSJ-UHFFFAOYSA-N C(C(O)C)(=O)O.C(CCCCCCCCCCCCCCCCC)[Na] Chemical compound C(C(O)C)(=O)O.C(CCCCCCCCCCCCCCCCC)[Na] AINDYVWBKIVNSJ-UHFFFAOYSA-N 0.000 description 1
- 244000122871 Caryocar villosum Species 0.000 description 1
- 244000228088 Cola acuminata Species 0.000 description 1
- 235000010205 Cola acuminata Nutrition 0.000 description 1
- 235000015438 Cola nitida Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 235000016975 Ribes fasciculatum Nutrition 0.000 description 1
- 241000735589 Ribes fasciculatum Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- GANNOFFDYMSBSZ-UHFFFAOYSA-N [AlH3].[Mg] Chemical class [AlH3].[Mg] GANNOFFDYMSBSZ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940069765 bean extract Drugs 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- XQGDCUULTKHHEM-UHFFFAOYSA-N butane-1,3-diol Chemical compound CC(O)CCO.CC(O)CCO XQGDCUULTKHHEM-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229940119429 cocoa extract Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical class O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940074052 glyceryl isostearate Drugs 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229940104257 polyglyceryl-6-dioleate Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001521 potassium lactate Substances 0.000 description 1
- 235000011085 potassium lactate Nutrition 0.000 description 1
- PHZLMBHDXVLRIX-UHFFFAOYSA-M potassium lactate Chemical compound [K+].CC(O)C([O-])=O PHZLMBHDXVLRIX-UHFFFAOYSA-M 0.000 description 1
- 229960001304 potassium lactate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 229910021647 smectite Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940098760 steareth-2 Drugs 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 229960001947 tripalmitin Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
含有α-羟基酸和进一步含有岩芹酸作为抗刺激/抗刺痛试剂的组合物。
Description
发明领域
本发明涉及岩芹酸在用于减小或消除由α-羟基酸引起的皮肤刺激性或刺痛的组合物和方法中的应用。
发明背景
已经证实α-羟基酸(AHA)类化合物可产生有益的美容作用，例如改善光损害或自然老化皮肤的外观，增亮皮肤，治疗老年斑等。不幸的是，其在高浓度时的应用偶尔可能与皮肤刺激有关，例如涂敷后肌肤变红并且有刺痛感。参见例如Kligman AM，《老年医学和皮肤病学杂志》(J.Geriatr.Dermatol.)1997；5(3)：128-131)。通过降低组合物中活性成分的含量或通过减小活性成分经皮肤的穿透性可以缓解刺激作用。这两种途径的严重缺陷均在于有损于美容功效。通过提高组合物的pH可以减小AHA类化合物的刺激性，但由于这种方法降低了AHA类化合物经皮肤的穿透性导致功效减小。人们希望减小或消除AHA类化合物的刺激作用但同时保持其功效。
欧洲专利申请0631722(Johnson & Johnson)公开了应用羟基乙酸来减小视黄醇引起的皮肤刺激性。美国专利5516793(Duffy)公开了应用抗坏血酸来缓解由多种包括AHA在内的局部用组分所引起的刺激性。
迄今已公开了富含岩芹酸的油类如芫荽子油在皮肤用化妆品组合物中的应用(EP 0709084 A2)。EP 0709084提出用芫荽子油作为增湿剂，但没有公开岩芹酸减小刺激性的特性。此外，提及了多种选择性存在的添加剂，例如溶角蛋白剂如羟基酸(正辛酰基5-水杨酸)。水杨酸是β-羟基酸，已知它是以不同于α-羟基酸的方式起作用并且已确定其刺激性较小。
上述现有技术未公开AHA类化合物和芫荽子油或岩芹酸在化妆品组合物中的联合形式，并且似乎没有教导应用岩芹酸来减小与使用AHA类化合物有关的刺激性和刺痛感。
发明概述
本发明部分涉及含有α-羟基酸(AHA)并且进一步含有岩芹酸的组合物。
本发明还涉及一种减小因局部涂敷含AHA类的组合物所致刺激或刺痛的美容方法，该方法包括局部涂敷岩芹酸来减小由组合物引起的刺激性。根据本发明的方法，岩芹酸可以与AHA类化合物共同存在于同一组合物中，或岩芹酸可以作为一种单独组合物涂敷。
根据本发明，由于局部涂敷了岩芹酸，从而减小或消除因局部涂敷AHA类化合物引起的刺激和刺痛。作为本发明的一部分现已发现不是所有抗刺激剂都能够缓解AHA所致刺激性。
本发明还涉及岩芹酸在减小AHA所致刺激或刺痛的化妆品组合物中的应用。
发明详述
所有用量是按组合物的重量计，除非另外规定。
岩芹酸(CH3(CH2)10CH＝CH(CH2)4COOH)是本发明组合物的必要成分。
岩芹酸在本发明组合物中的含量范围通常为该组合物的0.05％-20％(重量)，优选0.1％-10％(重量)，首选0.5％-5％(重量)。
AHA类化合物提高角质细胞的增殖并且增强神经酰胺的生物合成，增加表皮厚度，并且增强正常皮肤的脱屑致使皮肤看上去光滑、年轻。
AHA可以是立体异构体(DL，D或L)的联合形式。
AHA类化合物具有通式(1)：
其中M是氢或含有1-27个碳原子的饱和或不饱和、直链或支链的烃链。
特别优选的羟基酸选自乳酸、2-羟基辛酸、羟基月桂酸、羟基乙酸，和它们的混合物。当存在立体异构体时，首选L-异构体。
应理解，取决于组合物的pH值，羟基酸可以作为盐存在，例如铵或钾或钠盐。
虽然本发明组合物可以具有2.5-10的任何pH值，但当处于酸性pH时本发明组合物特别有效(尤其是如果它们含有羟基酸)，首选pH为3-4，因为如此条件下组合物特别有效。不幸的是，在此pH下组合物也有刺激性。
本发明组合物的特有优越性在于，可以采用较高含量的羟基酸或视黄醇而不引起皮肤刺激。羟基酸组分在本发明组合物中的适宜含量为0.01-20％(重量)，优选0.1-12％(重量)并且首选2-12％(重量)。
首选的含岩芹酸抗刺激剂的本发明组合物包含羟基乙酸和/或乳酸，因为虽已发现这些组分引起刺激，但也发现它们可特别有效地产生美容益处。
本发明的护肤组合物还含有化妆可接受赋形剂或载体，它们呈惰性，通常是以最高量存在的组分，并且起着提供活性或有效成分的作用。
除了水以外的赋形剂包括液体或固体柔润剂、溶剂、保湿剂、增稠剂和粉末。尤其优选的非水载体是聚二甲基硅氧烷和/或聚二甲基苯基硅氧烷。本发明的聚硅氧烷可以是粘度在25℃下为10-10 000000厘沲的那些。低粘度和高粘度聚硅氧烷的混合物尤其理想。这些聚硅氧烷购自通用电器公司以商标Vicasil、SE和SF，和Dow Corning公司以200和550系列出售的硅氧烷。聚硅氧烷在本发明组合物中的用量是该组合物重量的5-95％(重量)，优选25-90％(重量)。赋形剂的用量可以是组合物总重量的约2-约99％(重量)，优选约50-约99％(重量)，首选约80％-99％(重量)。
根据本发明，优选赋形剂至少60％(重量)是水，以赋形剂的重量计。本发明组合物优选是油-水乳化体，目的是增强羟基酸的皮肤转运(参见Sah A.，“有关不同剂型和产物结构对α-羟基酸转运的影响的体外研究”，MS论文，Cincinnati大学，药学院药学系，OH，1996.7)。如此改进的转运常常伴随着刺激性/刺痛感的增强，致使岩芹酸在此类乳剂中的应用特别必要。在优选的本发明水包油乳化体中，水占本发明乳化体的至少50％(重量)，首选50-70％(重量)，以组合物重量计。
选择性的皮肤有益物质和化妆品辅剂
本发明的化妆品组合物中可以存在不同种类的活性成分。活性成分被定义为除了润肤剂和仅改善组合物物理特征的成分以外的皮肤有益剂。虽然不局限在此类，通用实例包括抗皱化合物、防晒剂和鞣剂。
防晒剂包括那些常用于阻断紫外线的物质。化合物例是二氧化钛，PABA的衍生物，肉桂酸盐和水杨酸盐。例如，可以采用甲氧基肉桂酸辛酯和2-羟基-4-甲氧基二苯甲酮(也称作羟基甲氧基二苯甲酮)。甲氧基肉桂酸辛酯和2-羟基-4-甲氧基二苯甲酮分别以商标Parsol MCX和二苯甲酮-3出售。防晒剂在乳化体中的精确含量的变化可以取决于对紫外线预期的防护程度。
另一类存在于本发明化妆品组合物中的功能性成分是增稠剂。增稠剂的含量一般是该组合物重量的0.1-20％(重量)，优选约0.5％-10％(重量)。增稠剂实例是由B.F.Goodrich公司以商标Carbopol出售的交联聚丙烯酸酯物质。可采用的树胶例如是黄原胶、角叉菜胶、明胶、刺梧桐胶、果胶和槐树豆胶。在某些情况下，增稠功能可以由兼作聚硅氧烷或润肤剂的物质来实现。例如，粘度大于10厘沲的硅胶和酯如具有双重功能的甘油硬脂酸酯。
本发明化妆品组合物中可以混合有粉末。这些粉末包括白垩、滑石、漂白土、高岭土、淀粉、蒙脱石绿土、化学改性硅酸镁铝、有机改性蒙脱石、水合硅酸铝、火成二氧化硅、淀粉辛烯基琥珀酸铝及其混合物。
化妆品组合物中也可以混合其他少量辅助性组分。这些成分可以包括着色剂、遮光剂和香料。这些物质的含量是该组合物重量的0.001％-2％(重量)。
组合物的应用
本发明的组合物主要作为局部涂敷于人体皮肤的产品使用，尤其是皮肤调理和光滑试剂，并且可预防或减少外观的皱纹或皮肤老化。
在使用中，由适当容器或涂敷器中取少量组合物如1-10ml涂敷在皮肤的暴露区域上，如果必要，随后用手或手指或适当装置进行铺展和/或擦抹在皮肤上。
根据本发明的方法，通过局部涂敷的岩芹酸可减少或消除由活性成分引起的皮肤刺激。岩芹酸可以和活性成分共存，或可将岩芹酸与活性成分分开单独涂敷在皮肤上。
产品形式和包装
本发明的局部皮肤处理组合物可以被配制为洗剂、液体霜剂、霜剂或凝胶。该组合物可以包装在适合其粘度并且便于用户使用的适宜容器中。例如，洗剂和液体霜剂可以包装在瓶内或滚珠涂敷器中，或胶囊或抛射剂驱动气溶胶装置中，或装有适合手指操作的泵的容器。当组合物是霜剂时，可以将它直接贮藏在不变形瓶中或挤压容器中，例如管或有盖广口瓶内。
所以，本发明还提供一种密闭容器，该容器含有本发明定义的化妆上可接受的组合物。
岩芹酸可以与含有AHA类化合物的组合物分开包装。
下列特定实施例进一步说明本发明，但本发明不限于此。
对照实施例1
按照下列配方制备一种乳化体：
乳化体基本配方
| 完整的化学名称或CFTA命名 | 商品名和公认的％活性物质 | 重量％ |
| 水，DI | 46.54 | |
| EDTA二钠 | Sequesterene Na2 | 0.05 |
| 硅酸镁铝 | Veegum Ultra | 0.6 |
| 对羟基苯甲酸甲酯 | 对羟基苯甲酸甲酯 | 0.15 |
| 聚二甲基硅氧烷 | DC Antiform乳剂 | 0.01 |
| 1，3-丁二醇 | 1，3-丁二醇 | 3.0 |
| 羟乙基纤维素 | Natrosol 250HHR | 0.5 |
| 甘油，USP | 甘油USP | 2.0 |
| 黄原胶 | Keltrol 1000 | 0.2 |
| 三乙醇胺 | 三乙醇胺99(％) | 1.2 |
| 硬脂酸 | Pristerene 4911 | 3.0 |
| 对羟基苯甲酸丙酯NF | 对羟基苯甲酸丙酯NF | 0.1 |
| 甘油基氢化硬脂酸酯 | Naturechem GMHS | 1.5 |
| 硬脂基醇 | Lanette 18DEO | 1.5 |
| 棕榈酸异硬脂基酯 | Protachem ISP | 6.0 |
| 辛酸C12-C15醇酯 | Hetester FAP | 3.0 |
| 聚二甲基硅氧烷 | 聚硅氧烷液200(50cts) | 1.0 |
| 胆甾醇NF | 胆甾醇NF | 0.5 |
| 硬脂酸脱水山梨糖醇酯 | 硬脂酸脱水山梨糖醇酯 | 1.0 |
| 丁基化羟基甲苯 | Embanox BHT | 0.05 |
| 醋酸生育酚 | 醋酸维生素E | 0.1 |
| PEG-100硬脂酸酯 | MYRJ 59 | 2.0 |
| 硬脂酰基乳酸钠 | Pationic SSL | 0.5 |
| 棕榈酸视黄酯 | 棕榈酸维生素A 84％ | 0.06 |
| 羟基辛酸 | 羟基辛酸 | 0.1 |
| 水，DI | 适量至99.80 | |
| α-没药醇 | α-没药醇 | 0.2 |
| PH | 7-8 |
下表1中的附加组分代替水加入组合物中。
按照下述刺激试验方法进行对象测试。
刺激试验方法
4种暴露斑片试验：目的是对比由不同试验物质在反复斑片贴敷后所产生的刺激水平。试验物质在封闭条件下与皮肤接触。试验小组成员的外前臂被设计为涂敷区域。用绷带型敷料(Scanpor带)将斑片(25mm Hill TopChamber，带有直径为18mm的Webril填料的圆盘)固定在该位置。试验小组成员的双前臂均用来试验。斑片以平衡随机顺序贴敷。
斑片在星期一的早晨9:00贴敷并且在星期二早晨9:00除去(暴露24小时)。将一套新的斑片在星期二下午3:00贴敷并且在星期三早晨9:00除去(暴露18小时)。将第三套斑片在星期三下午3:00贴敷并且在星期四早晨9:00除去(暴露18小时)。将最后一套斑片在星期四下午3:00贴敷并且在星期五早晨9:00除去(暴露18小时)。
每次除去斑片时，用温水漂洗贴敷位置并且轻轻拍干。随后用外科皮肤标记笔将试验位点作出标记以确保定位进行等级评定并且随后贴敷斑片。在重新贴敷斑片之前，评估在星期二、三、四和五的下午3:00研究的试验位点。
可预见到试验位点的皮肤刺激，例如适度变红，干燥和/或发痒。试验位点可能肿胀。如果在评估时任何试验出现适度变红或肿胀，应不再贴敷该特定试验位点。
在连续光照下由两名有经验的检验人员目测评估每只手臂上的试验位点的等级。按照严重的等级对试验位点进行分类。在第一评估阶段在研究的每天连续评定试验位点，检验人员将反应分级。
在对反应评级时，反应最严重的位点给予最低的评分。次于最严重反应的位点给予第二最低评分，等等。评分不是强迫性的。如果两个或多个位点没有反应或反应相同(位点之间无差别)，可以得到评分的平均值。如果位点中断，根据刺激的程度，该位点保留中断给药时的评分。
统计学分析
利用非参数统计学方法在统计学意义上比较由斑片处理获得的等级评分结果。利用弗里德曼氏分级合计试验，对比含有抗刺激剂的试验物质与仅含有羟基酸和/或视黄醇类化合物的相应对照物。利用弗里德曼氏分析法由试验小组成员作为区组(即各试验成员采用各自的试验处理来测试)在各个评估点与配方2(对照)进行处理比较。p值小于0.1被认为具有显著性差异。
含有表1所述组分的组合物利用刺激试验方法来测试。对20名对象进行试验。分级之和越高，刺激的严重性越小。
表1
刺激试验结果
| 组合物 | 组分 | 分级之和(第4天) |
| 1 | 基础配方 | 68.5* |
| 2 | 对照：基础配方+8％羟基乙酸和0.075％视黄醇 | 46.5 |
| 3 | #2组合物+3％黑茶藨子油 | 58.0 |
| 4 | #2组合物+1％接骨木花 | 44.5 |
*明显小于#2组合物的刺激性。
由表1中在4种暴露后的结果可以看出，8％羟基乙酸和0.075％视黄醇(#2)明显比配方#1更刺激。1％接骨木花或3％黑茶藨子油无法明显降低刺激性。甚至由α-羟基酸引起的刺激也是一个应用熟知的抗刺激剂如接骨木花和黑茶藨子无法解决的问题。
对照实施例2
利用实施例1中所述的刺激试验方法测试含有表2所述组分的组合物1、5和11-14。17名对象接受试验。得到的结果概述于表2中。等级评分之和越高，刺激性越小。
表2
刺激试验结果
| 组合物# | 组分 | 分级之和(第4天) |
| 1 | 基础配方 | 74.5a |
| 5 | 基础配方+8％羟基乙酸+0.075％视黄醇 | 61.5 |
| 11 | #5组合物+1％绿茶 | 51.0 |
| 12 | #5组合物+0.1％K2甘草次酸 | 54.5 |
| 13 | #5组合物+3％Quench T* | 58.5 |
| 14 | #5组合物+3％多元醇预聚物-2** | 57.0 |
a统计学意义上刺激性明显小于#5组合物。
*Centerchem提供的抗刺激剂(含有水、丁二醇、可拉豆提取物、巴西可可提取物和冬青茶提取物)。
**Penederm，Inc.提供的抗刺激剂(CFTA命名为PPG-12/SMDI)。
由表2中的结果可以看出，没有哪一种试验的已知抗刺激剂能够明显减小#5组合物(含有8％羟基乙酸和0.075％视黄醇)引起的刺激性。
实施例3
此实施例证实局部涂敷的AHA类化合物使角质层释放出IL1-α。
已知角质层是促炎细胞因子IL-1α的储藏所(L.Wood，P.Elias，c.Calhoun，J.Tsai，C.Grunfeld，K.Feingold.“屏障破裂促进鼠表皮中白介素-1α的表达和由预形成集合体的释放”，《皮肤病学研究杂志》106：397-403，1996)。下列实施例说明局部涂敷AHA类化合物引起人体皮肤中IL-1α的释放。
IL-1α的离体免疫组织化学染色：
在冰上用进一步含有8％羟基乙酸(GA)pH3.8的基本配方(参见对照实施例1)或赋形剂霜剂(基本配方)或8％乳酸(LA)(pH3.8)的水溶液，或三羟甲基氨基甲烷缓冲液(pH7.6)处理人死体皮肤30分钟。钻取8mm活组织并且在甲醛中固定。用多克隆抗人IL-1α(R & D体系，1/50稀释)培养5μ切片，按照制造商在说明书中所述(Vector Labs)利用抗生物素蛋白-生物素-辣根过氧化物酶复合物法并且用2-氨基-9-乙基咔唑作为色原显影。用ImagePro Plus Version 3(MediaCybernetics，Silver Spring，MD)定量IL-1α的阳性标记(染色区域％)的强度。所得结果概括在表3中。
表3
| 8％乳酸 | 三羟甲基氨基甲烷缓冲液 | 8％羟基乙酸霜 | 赋形剂霜 | |
| 染色区域％ | 42.7±12* | 14.2±10.4 | 48.4±15.4** | 2.5±1.7 |
*通过t-试验与三羟甲基氨基甲烷缓冲液对比明显，p＜0.01
**通过t-试验与赋形剂对比明显，p＜0.03
由表3中的结果可以看出，用8％乳酸处理比其对照三羟甲基氨基甲烷缓冲液增强了IL-1α的染色。此外，用8％羟基乙酸霜比赋形剂明显增加了IL-1α染色。局部涂敷的AHA类(羟基乙酸和L-乳酸)可能促进了表皮中IL-1α的即时释放。角质层似乎是高水平IL-1α的最明显来源，已知它们储存在角质细胞内/四周。
AHA类化合物处理后释放的IL-1α能够诱发花生四烯酸级联，该级联将花生四烯酸转化为多种炎性代谢产物如前列腺素E2(PGE2)。前列腺素在炎症中起核心作用，由此与刺激的发病机理和治疗有关(Kupper T，“免疫学中：细胞和细胞因子(cytokines)在免疫和炎症中的作用”，Oppenheim JJ & Shevach EJ，牛津大学出版社，纽约，1990，285-305页)。
实施例4
下列实施例证实了岩芹酸可以有效抑制由IL-1α引起的PGE2感应，IL-1α是在AHA类化合物的作用下释放出来。所以，岩芹酸将有效减小由AHA类化合物引起的刺激。
新生儿皮层成纤维细胞(5-9传代)接种在96孔组织培养处理平板(Corning-Costar，Corning，NY)中，密度为7500细胞/孔。所用培养基是Dulbecco改进的Eagle氏培养基(DMEM)，高葡萄糖(Gibco/Life Technologies，Gaithersburg，MD)，补充有2mM L-谷酰胺，10％胎牛血清和抗生素和抗霉菌溶液(均也由LifeTechnologies提供)。48小时后，用200μl无血清DMEM漂洗各孔2次，向细胞施用200μl其中含有IL-1α1ng/ml和/或活性物质的DMEM+L-谷酰胺。6小时后，显微镜下检测细胞用来定性分析生存力，收回培养基并且冷冻直至进行分析。各种处理一式四份。
利用市售PGE2试剂盒(Amersham，Buckinghamshire，英国)进行酶免疫测定。将PGE2特异性抗体预涂敷在一套微量滴定孔中。试验基于未标记PGE2(标准品或样品)和固定量的过氧化物酶标记PGE2之间对有限量的充分结合的PGE2特异性抗体的竞争作用。4℃下采用0、1、2、4、8、16和32pg/孔的标准品或50μl培养基/孔与50μl/孔的0.1M磷酸盐缓冲液pH7.5一起培养3小时。培养结束时，向所有孔中加入50μl/孔辣根过氧化物酶轭合PGE2，并且将该平板在4℃下培养1小时。平板用300μl/孔0.01M磷酸盐缓冲液pH7.5洗涤4次，缓冲液中含有0.5％吐温20。加入存在于20％二甲基甲酰胺中的150μl/孔3，3，5，5-四甲基联苯胺/过氧化氢底物并且将平板在室温下准确培养30分钟。加入100μl/孔1M硫酸终止该反应。使用Dynatech MR7000显微平板分光光度计(Dynatech，Chantilly，VA)通过读取在450nm的吸光度定量测定孔中的颜色。绘制标准曲线并且由该曲线外推出样品中PGE2的含量。
利用化合物抑制IL-1α诱导的PGE2的能力可估计出试验化合物的抗炎效能。利用学生t试验测定抗炎显著性差异。所得结果概括在表4中。
表4
| 处理 | PGE2 pg/ml | 与IL-1α比较百分减少 |
| 对照 | 267.6±48.6 | |
| IL-1α | 598.2±118.3 | |
| IL-1α+0.01％岩芹酸 | 201.2±40.1 | 120％* |
| IL-1α+0.001％岩芹酸 | 308.3±97.2 | 80％ |
*与IL-1α单用时比较p＜0.05存在显著性差异
由表4中的结果可以看出，岩芹酸能够有效抑制IL-1α引起的PGE2感应，IL-1α是在AHA类化合物的作用下释放出来。所以，岩芹酸将有效减小由AHA类化合物引起的刺激。
实施例5-8说明了本发明的局部用组合物。这些组合物可以常规方式加工。它们适于美容应用。特别是，组合物适用于涂敷在起皱、粗糙、干燥、薄片状、老化和/或UV损害的皮肤上以改善皮肤的外观和感觉，并且适用于涂敷在健康皮肤上用来预防或延缓其恶化。
实施例5
在本发明的范围内的一种局部水包油乳化体如下所述：
化学名称 重量％
丙二醇 1
甘油 1
羟乙基纤维素 0.5
硅酸镁铝 0.5
咪唑啉基脲 0.5
EDTA 四钠 0.05
矿脂 2
棕榈酸异丙酯 5
聚二甲基硅氧烷 0.5
胆甾醇 0.5
鲸蜡醇 0.5
异硬脂酸 3
棕榈酸视黄酯 0.1
PEG-40硬脂酸酯 1
PEG-100硬脂酸酯 1
失水山梨糖醇硬脂酸酯 1
岩芹酸 0.5
羟基乙酸 7
氢氧化铵 至 pH4.0
水DI 适量至100％
实施例6
在本发明的范围内的另一种局部水包油乳化体如下所述：
化学名称 重量％
丙二醇 1
羟乙基纤维素 0.5
硅酸镁铝 0.5
咪唑啉基脲 0.2
矿脂 2
棕榈酸异丙酯 5
聚二甲基硅氧烷 0.5
胆甾醇 0.5
硬脂酸 3
异硬脂酸 1.5
棕榈酸甘油酯 1.5
PEG-40硬脂酸酯 1
PEG-100硬脂酸酯 1
失水山梨糖醇硬脂酸酯 1
鲸蜡醇 0.5
岩芹酸 2
羟基乙酸 10
氢氧化铵 至 pH3.8
水DI 适量至100％
实施例7
在本发明的范围内的一种局部油包水分散体如下所述：
化学名称 重量％
新戊酸异硬脂酸酯 20
PEG-8甘油辛/癸酸酯 6
辛酸鲸蜡基酯 17
聚二油酸甘油-6酯 15
环甲基硅酮 20
异硬脂酸甘油酯 0.5
异硬脂酸 0.5
神经酰胺皿 0.1
PPG-5-cetheth-20 3
L-乳酸/乳酸钾 6
羟基辛酸 0.1
水DI 1.3
岩芹酸 0.5
实施例8
在本发明的范围内的一种局部水包油乳化体如下所述：
化学名称 重量％
黄原胶 0.2
EDTA二钠 0.1
PCA钠 0.5
重氮联苯基(diazodinyl)脲 0.3
二氧化钛 1
硬脂酸 3
环甲基硅酮 0.3
鲸蜡醇 0.5
甘油基硬脂酸酯 0.5
PEG-100硬脂酸酯 0.5
Steareth-2 0.2
卵磷脂 0.5
生育酚 0.2
甲氧基肉桂酸辛酯 6
岩芹酸 0.5
羟基乙酸 3
苹果酸 2
乳酸 2
绿茶提取物 1
三乙醇胺 至pH3.8
水DI 适量至100％
应理解，这里所说明和描述的本发明的具体形式仅仅为代表性的。
Claims (3)
1.一种化妆品组合物，包括：
(i)占组合物重量0.01-20重量％的α-羟基酸，所述α-羟基酸选自乳酸、2-羟基辛酸、羟基月桂酸、羟基乙酸，和它们的混合物；
(ii)占组合物重量0.05％-20重量％的岩芹酸；和
(iii)美容可接受赋形剂。
2.权利要求1的化妆品组合物，其中所述α-羟基酸的含量是该组合物重量的0.1-12重量％。
3.权利要求1的化妆品组合物，其中α-羟基酸选自羟基乙酸、乳酸，和它们的混合物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/150841 | 1998-09-10 | ||
| US09/150,841 US6022896A (en) | 1998-09-10 | 1998-09-10 | Petroselinic acid as an anti-irritant in compositions containing alpha-hydroxy acids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1325297A CN1325297A (zh) | 2001-12-05 |
| CN1205914C true CN1205914C (zh) | 2005-06-15 |
Family
ID=22536214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB998130915A Expired - Lifetime CN1205914C (zh) | 1998-09-10 | 1999-05-05 | 化妆品组合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6022896A (zh) |
| EP (1) | EP1109527B1 (zh) |
| JP (1) | JP4129121B2 (zh) |
| KR (1) | KR100590141B1 (zh) |
| CN (1) | CN1205914C (zh) |
| AR (1) | AR018357A1 (zh) |
| AU (1) | AU740627B2 (zh) |
| BR (1) | BR9913589A (zh) |
| CA (1) | CA2343130C (zh) |
| CZ (1) | CZ293631B6 (zh) |
| DE (1) | DE69902473T2 (zh) |
| ES (1) | ES2181501T3 (zh) |
| ID (1) | ID29403A (zh) |
| MX (1) | MXPA01002531A (zh) |
| PL (1) | PL196079B1 (zh) |
| RU (1) | RU2217125C2 (zh) |
| TW (1) | TW550072B (zh) |
| WO (1) | WO2000015179A2 (zh) |
| ZA (1) | ZA200101828B (zh) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1013178B2 (en) † | 1998-12-22 | 2009-09-16 | Unilever N.V. | Cosmetic use of petroselinic acid |
| GB9918022D0 (en) * | 1999-07-30 | 1999-09-29 | Unilever Plc | Skin care composition |
| GB9918023D0 (en) * | 1999-07-30 | 1999-09-29 | Unilever Plc | Skin care composition |
| CA2397198C (en) * | 2000-03-06 | 2011-06-21 | Unilever Plc | Echinacea extract as anti-irritant and anti-aging booster in cosmetic compositions |
| US6410036B1 (en) | 2000-05-04 | 2002-06-25 | E-L Management Corp. | Eutectic mixtures in cosmetic compositions |
| US6756032B1 (en) | 2000-07-12 | 2004-06-29 | The Procter & Gamble Company | Method to enhance and/or prolong the effects of a primary challenge to a responsive system with a secondary challenge |
| DE10063660A1 (de) * | 2000-12-20 | 2002-07-04 | Beiersdorf Ag | Kosmetische und dermatologische Zubereitungen in Form von O/W-Emulsionen mit einem Gehalt an Sterinen und/oder C¶1¶¶2¶-C¶4¶¶0¶-Fettsäuren |
| DE10063658A1 (de) * | 2000-12-20 | 2002-07-04 | Beiersdorf Ag | Kosmetische und dermatologische Zubereitungen in Form von W/O/W-Emulsionen mit einem Gehalt an Sterinen und /oder C12-C-40-Fettsäure |
| DE10139582A1 (de) * | 2001-08-10 | 2003-02-20 | Beiersdorf Ag | Kosmetische und dermatologische Zubereitungen in Form von W/O/W-Emulsionen mit einem Gehalt an Sterinen und/oder C12-C40-Fettsäuren |
| DE10139580A1 (de) * | 2001-08-10 | 2003-02-20 | Beiersdorf Ag | Kosmetische und dermatologische Zubereitungen in Form von O/W-Emulsionen mit einem Gehalt an Sterinen und/oder C12-C40-Fettsäuren |
| US6919088B2 (en) | 2002-06-05 | 2005-07-19 | Rolland F. Hebert | Water-soluble stable salts of petroselinic acid |
| DE10326899A1 (de) | 2003-06-14 | 2004-12-30 | Beiersdorf Ag | Kosmetische Zubereitungen mit stabilisierten Konservierungsmitteln |
| GB0425945D0 (en) * | 2004-11-26 | 2004-12-29 | Unilever Plc | Underarm cosmetic method and compositions |
| FR2893252B1 (fr) | 2005-11-17 | 2008-02-15 | Engelhard Lyon Sa | Extraits vegetaux stimulant has2 |
| EP1932509A1 (fr) * | 2006-12-14 | 2008-06-18 | L'oreal | Utilisation orale d'au moins un acide gras monoinsaturé pour améliorer la chevelure |
| WO2008078050A2 (fr) * | 2006-12-14 | 2008-07-03 | L'oreal | Utilisation d'au moins un acide gras mono-insature pour le traitement des peaux, muqueuses ou semi-muqueuses et cuirs chevelus fragiles |
| PT1932510E (pt) * | 2006-12-14 | 2016-06-16 | Oreal | Utilização de pelo menos um ácido gordo monoinsaturado para o tratamento das peles, das mucosas e dos couros cabeludos frágeis |
| US20090137534A1 (en) * | 2007-11-26 | 2009-05-28 | Chaudhuri Ratan K | Skin treatment compositions and methods |
| EA019677B1 (ru) * | 2008-04-16 | 2014-05-30 | Юнайтед Текнолоджис Ут Аг | Применение интерлейкина-1 альфа для приготовления композиций для увеличения плотности коллагена и эластина в коже |
| WO2010145655A1 (en) * | 2009-06-19 | 2010-12-23 | Rexcure V/Jan Enggaard | Herbal extract composition comprising petroselinum and ocimum extract |
| WO2015110278A1 (en) | 2014-01-27 | 2015-07-30 | Unilever Plc | Composition |
| JP6553372B2 (ja) * | 2015-02-17 | 2019-07-31 | ジェイオーコスメティックス株式会社 | 化粧料 |
| MX368097B (es) | 2015-04-28 | 2019-09-19 | Unilever Nv | Compuestos de n-aralquilcarbonildiamina y composiciones para el cuidado personal que comprende los mismos. |
| EP3288926B1 (en) | 2015-04-28 | 2021-01-20 | Unilever PLC | N-aralkylcarbonyl-piperazine and -homopiperazine compounds and personal care compositions comprising the same |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0116439A3 (en) * | 1983-02-02 | 1986-01-29 | Suntory Limited | Fatty acid containing hair tonic composition |
| FR2599253B1 (fr) * | 1986-05-30 | 1989-03-17 | Clarins | Produit liquide pour le traitement esthetique de la peau et son procede de fabrication. |
| CH679119A5 (zh) * | 1988-05-13 | 1991-12-31 | Sandoz Ag | |
| US4966754A (en) * | 1988-08-08 | 1990-10-30 | Aveda Corporation | Preservation of cosmetic compositions |
| EP0355842A3 (en) * | 1988-08-26 | 1990-05-16 | Sansho Seiyaku Co., Ltd. | External preparation |
| US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
| JP3649341B2 (ja) * | 1990-06-15 | 2005-05-18 | 株式会社資生堂 | 複合体及び複合体の組成物及び乳化剤組成物並びに乳化組成物 |
| US5380894A (en) * | 1991-03-01 | 1995-01-10 | The United States Of America As Represented By The Secretary Of Agriculture | Production of hydroxy fatty acids and estolide intermediates |
| US5422371A (en) * | 1992-05-27 | 1995-06-06 | Arch Development Corp. | Methods and compositions for inhibiting 5α-reductase activity |
| US5516793A (en) * | 1993-04-26 | 1996-05-14 | Avon Products, Inc. | Use of ascorbic acid to reduce irritation of topically applied active ingredients |
| AU688757B2 (en) * | 1993-05-27 | 1998-03-19 | Johnson & Johnson Consumer Products, Inc. | Retinoid composition |
| FR2714602B1 (fr) * | 1993-12-30 | 1996-02-09 | Oreal | Composition antiacnéique pour le traitement simultané des couches superficielles et profondes de la peau, son utilisation. |
| FR2714831B1 (fr) * | 1994-01-10 | 1996-02-02 | Oreal | Composition cosmétique et/ou dermatologique contenant des dérivés d'acide salicylique et procédé de solubilisation de ces dérivés. |
| FR2725370B1 (fr) * | 1994-10-07 | 1997-06-06 | Oreal | Composition cosmetique ou dermatologique contenant une huile riche en acide petroselinique |
| AU4824997A (en) * | 1996-10-17 | 1998-05-11 | Bristol-Myers Squibb Company | Antimicrobial lipids |
| DE19703745C2 (de) * | 1997-02-03 | 1998-11-26 | Henkel Kgaa | Stückseifen |
| ATE386439T1 (de) * | 1997-05-27 | 2008-03-15 | Sembiosys Genetics Inc | Verwendungen von ölkörpern |
| EP0888773A1 (fr) * | 1997-07-05 | 1999-01-07 | Societe Des Produits Nestle S.A. | Utilisation de l'acide pétrosélinique pour le traitement des inflammations des tissus superficiels |
-
1998
- 1998-09-10 US US09/150,841 patent/US6022896A/en not_active Expired - Lifetime
-
1999
- 1999-05-05 WO PCT/EP1999/003234 patent/WO2000015179A2/en active IP Right Grant
- 1999-05-05 ID IDW20010567A patent/ID29403A/id unknown
- 1999-05-05 CN CNB998130915A patent/CN1205914C/zh not_active Expired - Lifetime
- 1999-05-05 DE DE69902473T patent/DE69902473T2/de not_active Expired - Lifetime
- 1999-05-05 ES ES99969017T patent/ES2181501T3/es not_active Expired - Lifetime
- 1999-05-05 CZ CZ2001886A patent/CZ293631B6/cs not_active IP Right Cessation
- 1999-05-05 PL PL346866A patent/PL196079B1/pl not_active IP Right Cessation
- 1999-05-05 BR BR9913589-2A patent/BR9913589A/pt not_active Application Discontinuation
- 1999-05-05 MX MXPA01002531A patent/MXPA01002531A/es active IP Right Grant
- 1999-05-05 RU RU2001109436/15A patent/RU2217125C2/ru active
- 1999-05-05 EP EP99969017A patent/EP1109527B1/en not_active Expired - Lifetime
- 1999-05-05 KR KR1020017003077A patent/KR100590141B1/ko not_active IP Right Cessation
- 1999-05-05 JP JP2000569764A patent/JP4129121B2/ja not_active Expired - Lifetime
- 1999-05-05 AU AU42597/99A patent/AU740627B2/en not_active Ceased
- 1999-05-05 CA CA002343130A patent/CA2343130C/en not_active Expired - Lifetime
- 1999-05-14 AR ARP990102294A patent/AR018357A1/es active IP Right Grant
- 1999-05-31 TW TW088109091A patent/TW550072B/zh not_active IP Right Cessation
-
2001
- 2001-03-05 ZA ZA200101828A patent/ZA200101828B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2343130C (en) | 2007-07-31 |
| ZA200101828B (en) | 2002-03-05 |
| WO2000015179A3 (en) | 2000-08-03 |
| DE69902473T2 (de) | 2003-07-03 |
| CZ2001886A3 (cs) | 2001-08-15 |
| JP4129121B2 (ja) | 2008-08-06 |
| TW550072B (en) | 2003-09-01 |
| DE69902473D1 (de) | 2002-09-12 |
| MXPA01002531A (es) | 2003-07-14 |
| KR100590141B1 (ko) | 2006-06-15 |
| US6022896A (en) | 2000-02-08 |
| PL196079B1 (pl) | 2007-12-31 |
| BR9913589A (pt) | 2001-06-05 |
| AU740627B2 (en) | 2001-11-08 |
| AU4259799A (en) | 2000-04-03 |
| EP1109527B1 (en) | 2002-08-07 |
| CZ293631B6 (cs) | 2004-06-16 |
| EP1109527A2 (en) | 2001-06-27 |
| AR018357A1 (es) | 2001-11-14 |
| PL346866A1 (en) | 2002-03-11 |
| JP2002524482A (ja) | 2002-08-06 |
| RU2217125C2 (ru) | 2003-11-27 |
| KR20010086399A (ko) | 2001-09-10 |
| WO2000015179A2 (en) | 2000-03-23 |
| ES2181501T3 (es) | 2003-02-16 |
| ID29403A (id) | 2001-08-30 |
| CA2343130A1 (en) | 2000-03-23 |
| CN1325297A (zh) | 2001-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1205914C (zh) | 化妆品组合物 | |
| CN1230148C (zh) | 包含n－乙烯基咪唑聚合物或共聚物和氧化敏感亲水有效成分的组合物的化妆用途 | |
| CN1226991C (zh) | 在含羟酸或视黄醛衍生物的组合物中作为抗刺激剂的姜黄 | |
| CN1100528C (zh) | 在包含羟基酸或类视色素的组合物中作为抗刺激剂的琉璃苣种子油 | |
| CN1243537C (zh) | 含有通过至少一种马来酸酐共聚物稳定化的至少一种氧化敏感性亲水性活性成分的组合物的化妆上和 /或皮肤上的用途 | |
| CN1321627C (zh) | 在化妆品组合物中作为抗刺激剂和抗老化促进剂的松果菊提取物 | |
| JP3802034B2 (ja) | ベツリン酸を含む化粧品組成物 | |
| TWI255188B (en) | Cosmetic compositions containing resveratrol and retinoids | |
| JP3611657B2 (ja) | 乳酸デヒドロゲナーゼ阻害剤を含む化粧品組成物 | |
| CN1781906A (zh) | 半胱氨酸衍生物 | |
| CN1202817A (zh) | 通过破坏隔离层对结构退化皮肤进行的护理 | |
| CN1627934A (zh) | 洗去型皮肤调理组合物 | |
| CN1327380A (zh) | 化妆组合物 | |
| CN1105554C (zh) | 包含能模拟视黄酸对皮肤之作用的化合物结合物的护肤组合物 | |
| CN1196237A (zh) | 含有羟基酸或类视色素的组合物 | |
| CN1787806A (zh) | 皮肤病的局部治疗 | |
| CN1225237C (zh) | 护理皮肤的化妆方法 | |
| CN109464337A (zh) | 紧致祛皱精华 | |
| JP6282582B2 (ja) | 皮膚老化の徴候を低減または遅延させるための、ジンゲロンまたはその誘導体の使用 | |
| CN1172657C (zh) | 含支链酯的抗皮脂护肤化妆品组合物 | |
| WO2012051374A2 (en) | Use of monoamine oxidase inhibitors to improve epithelial biology | |
| CN1188109C (zh) | 含岩芹酸的护肤组合物 | |
| TW201028170A (en) | Topical compositions containing Cis-6-nonenol and its derivatives and methods for treating skin | |
| US20030198657A1 (en) | Methods using phytol to improve the appearance of skin and compositions for such methods | |
| FR2740340A1 (fr) | Utilisation d'acides carboxyliques porteurs d'une fonction soufree pour favoriser la desquamation de la peau ou stimuler le renouvellement epidermique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| C10 | Entry into substantive examination | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20050615 |